CSL LIMITED (CSL.AU) saw its shares plummet 7.73% during intraday trading on Thursday, marking a significant decline for the biopharmaceutical heavyweight.

The sharp drop follows the release of the company's financial results, which revealed a substantial compression in net margins. CSL's trailing 12-month net margin fell to 9.1%, a significant decline from 18% a year earlier, partly due to a one-off loss of approximately US$2.1 billion that weighed on reported profitability. Furthermore, the company's earnings have shown notable volatility, with half-yearly EPS swinging from US$1.53 in H2 2024 to US$4.15 in H1 2025, then back to US$2.05 in H2 2025.

Investor concerns were amplified by CSL's premium valuation, with the stock trading at a trailing P/E of 40.2x compared to peers at 33.8x, while also carrying high debt and showing weak dividend coverage on trailing earnings. This company-specific weakness occurred even as the broader Australian market advanced, with the S&P/ASX 200 reclaiming the 9,000-point mark, highlighting that CSL's challenges were distinct from the overall market trend.